
PaySign Inc (PAYS) Stock Forecast & Price Target
PaySign Inc (PAYS) Analyst Ratings
Bulls say
PaySign is benefiting from a powerful mix of rapid Patient Affordability expansion, share gains, and improving profitability, with Pharma revenue jumping 89% Y/Y to $14.6M in 2Q26 and representing 52% of total revenue. The company added 17 net new campaigns in the first half of 2026, exited 2Q26 with 148 active programs, and management indicated it could match or surpass the 55 net additions achieved in 2025, while dynamic business rules reportedly saved clients more than $325M in 2025 with 97% accuracy. Strong liquidity and execution reinforce the outlook, as 2Q adjusted free cash flow reached $6.8M, unrestricted cash was $27.4M, restricted cash was $149.1M, debt was zero, and 2Q26 adjusted EBITDA rose 113% Y/Y to $9.6M with margins expanding to 34.0%.
Bears say
PaySign is exposed to a difficult competitive landscape in prepaid card programs, where larger rivals and new entrants can pressure pricing and contract terms, limiting its ability to scale profitably. Its fundamentals also hinge on concentrated risks: a small number of bank partners, heavy regulatory oversight, and a domestic Plasma Donor Compensation niche that generated just over 55% of revenue in 2025, leaving results vulnerable to donation volumes, regulatory shifts, or customer consolidation. In addition, data security risks, along with roughly 25% insider ownership and a low float, raise concerns about operational disruption, minority shareholder influence, and share volatility.
This aggregate rating is based on analysts' research of PaySign Inc and is not a guaranteed prediction by Public.com or investment advice.
PaySign Inc (PAYS) Analyst Forecast & Price Prediction
Start investing in PaySign Inc (PAYS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About PaySign Inc (PAYS) Forecast
PaySign Inc (PAYS) Analyst Forecast & Price Prediction
Start investing in PaySign Inc (PAYS)
Order type
Buy in
Order amount
Est. shares
0 shares